A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Metastatic, castrate resistant prostate cancer (M1 by National Comprehensive Cancer
Network (NCCN) criteria)

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone
(GnRH) analogue or a surgical/medical castration with testosterone level of
≤1.73nmol/L (50ng/dL)

- Patients with skeletal system symptoms who are already on medications to strengthen
bones are allowed if they were started ˃28 days before study treatment

- Bone-directed radiotherapy to pelvic region for ease of pain from painful bone
metastases is allowed up to 14 days before

Exclusion Criteria:

- Cancer that has spread to the liver or brain

- Active, known, or suspected autoimmune disease or infection

- Prior treatment with any drug that targets T cell co-stimulation pathways(such as
checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria could apply